. Facing risk of contracting COVID-19, adopting individual health and safety behaviors to prevent infection was critical for first responders to ensure personal and public safety. This study assessed direct and indirect relationships between safety leadership, safety behaviors and the effect of risk perceptions on these relationships among aircraft rescue and firefighting (ARFF) personnel during the COVID-19 pandemic. . A total of 127 ARFF frontline personnel participated in an online survey. COVID-19-specific constructs of safety leadership, safety behaviors and risk perceptions were assessed using a structural model with moderation and serial mediation analysis using the mixed-model method. . Safety leadership had significant direct effects on safety compliance and indirect effects on safety participation and mask use. ARFF personnel's perceived severity of the virus had significant direct effects on mask use and indirect effects on safety compliance and participation behaviors. The interaction of safety leadership and perceived susceptibility to the virus had significant direct effects on safety compliance behaviors and indirect effects on safety participation and mask use. . There are practical implications to strengthen safety compliance behaviors through leadership. This study contributes to the literature on leadership and safety behaviors among ARFF personnel during exceptional circumstances and times of crisis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10803548.2024.2414577 | DOI Listing |
AJOG Glob Rep
February 2025
Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL (Steinberg, Young, Strom, Andebrhan, Perry, Barry, Holder, Roque, and Yee).
Background: In obstetrics and gynecology (OBGYN) research, gender disparities permeate through leadership, funding, promotion, mentorship, publishing, compensation, and publicity. Few studies have investigated OBGYN clinical trial leadership as it relates to investigator gender. Thus, we undertook an investigation of principal investigator (PI) gender and clinical trial success.
View Article and Find Full Text PDFIDCases
December 2024
Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms. Given its long half-life, a two-dose regimen can provide effective systemic therapy for up to six weeks, making it an appealing option to avoid prolonged intravenous antibiotic therapy. Herein, we report a case of a 27-year-old male who developed dalbavancin-induced fever while treating Methicillin-sensitive (MSSA) bacteremia.
View Article and Find Full Text PDFBackground: Spirometry-based assessment of pulmonary function has limitations in detecting pulmonary toxicity following cancer treatment with chemotherapy, haematopoietic stem cell transplantation, radiotherapy or thoracic surgery. Nitrogen single and multiple breath washout tests are sensitive in assessing peripheral airway function, and lung imaging detects structural abnormalities, but little is known about their use in paediatric cancer patients and survivors. We aimed to 1) identify studies using nitrogen single or multiple breath washout tests and/or lung imaging to assess pulmonary toxicity in paediatric cancer patients and survivors, and 2) describe reported abnormalities.
View Article and Find Full Text PDFJ Interprof Care
January 2025
Department of Nursing, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS®) is a strategy for improving communication and team climate in hospitals. While it shows promise, it remains an untested tool among health care professional teams. A cross-sectional design with survey methodology was implemented.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!